AstraZeneca Presents Compelling Data at ASCO for Imfinzi in Lung Cancer and Lynparza for Breast Cancer

AstraZeneca Presents Compelling Data at ASCO for Imfinzi in Lung Cancer and Lynparza for Breast Cancer

AstraZeneca presented data from two phase 3 trials at the annual American Society for Clinical Oncology (ASCO) meeting. The first data presentation was for the PACIFIC trial, which evaluated Imfinzi (durvalumab) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT). Data demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years. The second presentation was for the OlympiA trial, showed Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

The PACIFIC trial was a randomized, double-blinded, placebo-controlled trial of Imfinzi as treatment in ‘all-comer’ patients (regardless of PD-L1 status) with unresectable, Stage III NSCLC whose disease had not progressed following concurrent platinum-based CRT. The trial was conducted at 235 center...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee